Abstract
Purpose
Huntington disease (HD) is an autosomal dominant neurodegenerative disease which results in several progressive symptoms, including bulbar dysfunction (i.e., speech and swallowing difficulties). Although difficulties in speech and swallowing in HD have a negative impact on health-related quality of life, no patient-reported outcome measure exists to capture these difficulties that are specific to HD. Thus, we developed a new patient-reported outcome measure for use in the Huntington Disease Health-Related Quality of Life (HDQLIFE) Measurement System that focused on the impact that difficulties with speech and swallowing have on HRQOL in HD.
Methods
Five hundred and seven individuals with prodromal and/or manifest HD completed 47 newly developed items examining speech and swallowing difficulties. Unidimensional item pools were identified using exploratory factor analysis and confirmatory factor analysis (EFA and CFA, respectively). Item response theory (IRT) was used to calibrate the final measures.
Results
EFA and CFA identified two separate unidimensional sets of items: Speech Difficulties (27 items) and Swallowing Difficulties (16 items). Items were calibrated separately for these two measures and resulted in item banks that can be administered as computer adaptive tests (CATs) and/or 6-item, static short forms. Reliability of both of these measures was supported through high correlations between the simulated CAT scores and the full item bank.
Conclusions
CATs and 6-item calibrated short forms were developed for HDQLIFE Speech Difficulties and HDQLIFE Swallowing Difficulties. These measures both demonstrate excellent psychometric properties and may have clinical utility in other populations where speech and swallowing difficulties are prevalent.
Similar content being viewed by others
References
Roos, R. A. C., Hermans, J., Vegtervandervlis, M., Vanommen, G. J. B., & Bruyn, G. W. (1993). Duration of illness in Huntingtons-disease is not related to age at onset. Journal of Neurology, Neurosurgery and Psychiatry, 56(1), 98–100.
Albin, R. L., Reiner, A., Anderson, K. D., Penney, J. B., & Young, A. B. (1990). Striatal and nigral neuron subpopulations in rigid huntingtons-disease—implications for the functional-anatomy of chorea and rigidity-Akinesia. Annals of Neurology, 27(4), 357–365.
Coyle, J. T., & Schwarcz, R. (1976). Lesion of striatal neurons with kainic acid provides a model for huntingtons-chorea. Nature, 263(5574), 244–246.
Marshall, F. J., Walker, F., Frank, S., Oakes, D., Plumb, S., Factor, S. A., et al. (2006). Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology, 66(3), 366–372.
Metman, L. V., Morris, M. J., Farmer, C., Gillespie, M., Mosby, K., Wuu, J., & Chase, T. N. (2002). Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine. Neurology, 59(5), 694–699.
Hartelius, L., Carlstedt, A., Ytterberg, M., Lillvik, M., & Laakso, K. (2003). Speech disorders in mild and moderate Huntington disease: Results of dysarthria assessments of 19 individuals. Journal of Medical Speech-Language Pathology, 11(1), 1–14.
Skodda, S., Schlegel, U., Hoffmann, R., & Saft, C. (2014). Impaired motor speech performance in premotor stages of Huntington’s disease (HD) over time - A longitudinal investigation. Movement Disorders, 29, S217.
Heemskerk, A. W., & Roos, R. A. C. (2011). Dysphagia in Huntington’s disease: A review. Dysphagia, 26(1), 62–66.
Lanska, D. J., Lavine, L., Lanska, M. J., & Schoenberg, B. S. (1988). Huntingtons-disease mortality in the United-States. Neurology, 38(5), 769–772.
Sorensen, S. A., & Fenger, K. (1992). Causes of death in patients with Huntington’s-disease and in unaffected 1st degree relatives. Journal of Medical Genetics, 29(12), 911–914.
Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. (1996). Mov Disord, 11(2), 136–142.
Basch, E. (2010). The missing voice of patients in drug-safety reporting. New England Journal of Medicine, 362(10), 865–869.
Cella, D., Nowinski, C., Peterman, A., Victorson, D., Miller, D., Lai, J.-S., & Moy, C. (2011). The neurology quality of life measurement (Neuro-QOL) initiative. Archives of Physical Medicine and Rehabilitation, Supplement, 92(Suppl 1), S28–S36.
Gershon, R. C., Lai, J. S., Bode, R., Choi, S., Moy, C., Bleck, T., Miller, D., Peterman, A., & Cella, D. (2012). Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Quality of Life Research, 21(3), 475–486.
Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., et al. (2010). The patient-reported outcomes measurement information system (PROMIS) developed and tested in its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology, 63, 1179–1194.
Heemskerk, A. W., Verbist, B. M., Marinus, J., Heijnen, B., Sjogren, E. V., & Roos, R. A. C. (2014). The Huntington’s disease dysphagia scale. Movement Disorders, 29(10), 1312–1316.
McHorney, C. A., Martin-Harris, B., Robbins, J., & Rosenbek, J. (2006). Clinical validity of the SWAL-QOL and SWAL-CARE outcome tools with respect to bolus flow measures. Dysphagia, 21(3), 141–148.
McHorney, C. A., Robbins, J., Lomax, K., Rosenbek, J. C., Chignell, K., Kramer, A. E., & Bricker, D. E. (2002). The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III Documentation of reliability and validity. Dysphagia, 17(2), 97–114.
Carlozzi, N. E., Schilling, S. G., J.-S., L., Paulsen, J. S., Hahn, E. A., Perlmutter, J. S., Ross, C. A., Downing, N. R., Kratz, A. L., McCormack, M. K., Nance, M. A., Quaid, K. A., Stout, J., Gershon, R. C., Ready, R., Miner, J. A., Barton, S. K., Perlman, S. L., Rao, S. M., Frank, S., Shoulson, I., Marin, H., Geschwind, M. D., Dayalu, P., Foroud, T., Goodnight, S. M., & Cella, D. (in press). HDQLIFE: Development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research.
Carlozzi, N. E., Downing, N. R., McCormack, M. K., Schilling, S. G., Perlmutter, J. S., Hahn, E. A., Lai, J.-S., Frank, S., Quaid, K. A., Paulsen, J. S., Cella, D., Goodnight, S. M., Miner, J. A., & Nance, M. A. (in press). New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient reported outcomes measurement system). Quality of Life Research.
Carlozzi, N. E., Downing, N. R., Schilling, S. G., J.-S., L., Goodnight, S. M., Miner, J. A., & Frank, S. (in press). The development of a new computer adaptive test to evaluate chorea in Huntington Disease: HDQLIFE Chorea. Quality of Life Research.
PROMIS® Instrument Development and Psychometric Evaluation Scientific Standards. http://www.nihpromis.org/Documents/PROMIS_Standards_050212.pdf.
Hanauer, D. A., Mei, Q., Law, J., Khanna, R., & Zheng, K. (2015). Supporting information retrieval from electronic health records: A report of University of Michigan’s nine-year experience in developing and using the electronic medical record search engine (EMERSE). Journal of Biomedical Informatics, 55, 290–300.
Paulsen, J. S., Hayden, M., Stout, J. C., Langbehn, D. R., Aylward, E., Ross, C. A., et al. (2006). Preparing for preventive clinical trials—The predict-HD study. Archives of Neurology, 63(6), 883–890.
Carlozzi, N. E., & Tulsky, D. S. (2013). Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. Journal of Health Psychology, 18(2), 212–225.
Shoulson, I., & Fahn, S. (1979). Huntington disease—clinical care and evaluation. Neurology, 29(1), 1–3.
Muthén, L. K., & Muthén, B. O. (2011). Mplus user’s guide. Los Angeles, CA: Muthén and Muthén.
Cook, K. F., Kallen, M. A., & Amtmann, D. (2009). Having a fit: impact of number of items and distribution of data on traditional criteria for assessing IRT’s unidimensionality assumption. Quality of Life Research, 18(4), 447–460.
Reise, S. P., Morizot, J., & Hays, R. D. (2007). The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Quality of Life Research, 16(Suppl 1), 19–31.
McDonald, R. P. (1999). Test theory: A unified treatment. Mahwah: Lawrence Erlbaum Associates Inc.
Samejima, F., van der Liden, W. J., & Hambleton, R. (1996). The graded response model. In W. J. van der Liden (Ed.), Handbook of modern item response theory (pp. 85–100). NY, NY: Springer.
Cai, L., Thissen, D., & du Toit, S. H. C. (2011). IRTPRO for windows [Computer software]. Lincolnwood, IL: Scientific Software International.
Crane, P. K., Gibbons, L. E., Jolley, L., & van Belle, G. (2006). Differential item functioning analysis with ordinal logistic regression techniques, DIFdetect and difwithpar. Medical Care, 44(11 Suppl 3), S115–S123.
Choi, S. W., Gibbons, L. E., & Crane, P. K. (2011). lordif: An R package for detecting differential item functioning using iterative hybrid ordinal logistic regression/item response theory and monte carlo simulations. Journal of Statistical Software, 39(8), 1–30.
Choi, S. W. (2009). Firestar: Computerized adaptive testing simulation program for polytomous item response theory models. Applied Psychological Measurement, 33(8), 644–645.
Acknowledgments
Work on this manuscript was supported by the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (R01NS077946) and the National Center for Advancing Translational Sciences (UL1TR000433). In addition, a portion of this study sample was collected in conjunction with the Predict-HD study. The Predict-HD was supported by the NIH, National Institute of Neurological Disorders and Stroke (R01NS040068), the NIH, Center for Inherited Disease Research (provided supported for sample phenotyping), and the CHDI Foundation (award to the University of Iowa). Jennifer Waljee’s effort was supported in part by a Mentored Clinical Investigator Award through the Agency for Healthcare Research and Quality (K08HS023313). We thank the University of Iowa, the Investigators and Coordinators of this study, the study participants, the National Research Roster for Huntington Disease Patients and Families, the Huntington Study Group, and the Huntington’s Disease Society of America. We acknowledge the assistance of Jeffrey D. Long, Hans J. Johnson, Jeremy H. Bockholt, Roland Zschiegner, and Jane S. Paulsen. We also acknowledge Roger Albin, Kelvin Chou, and Henry Paulsen for the assistance with participant recruitment. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
HDQLIFE Site Investigators and Coordinators
Noelle Carlozzi, Praveen Dayalu, Stephen Schilling, Amy Austin, Matthew Canter, Siera Goodnight, Jennifer Miner, Nicholas Migliore (University of Michigan, Ann Arbor, MI); Jane Paulsen, Nancy Downing, Isabella DeSoriano, Courtney Shadrick, Amanda Miller (University of Iowa, Iowa City, IA); Kimberly Quaid, Melissa Wesson (Indiana University, Indianapolis, IN); Christopher Ross, Gregory Churchill, Mary Jane Ong (Johns Hopkins University, Baltimore, MD); Susan Perlman, Brian Clemente, Aaron Fisher, Gloria, Obialisi, Michael Rosco (University of California-Los Angeles, Los Angeles, CA); Michael McCormack, Humberto Marin, Allison Dicke (Rutgers University, Piscataway, NJ); Joel Perlmutter, Stacey Barton, Shineeka Smith (Washington University, St. Louis, MO); Martha Nance, Pat Ede (Struthers Parkinson’s Center); Stephen Rao, Anwar Ahmed, Michael Lengen, Lyla Mourany, Christine Reece, (Cleveland Clinic Foundation, Cleveland, OH); Michael Geschwind, Joseph Winer (University of California – San Francisco, CA), David Cella, Richard Gershon, Elizabeth Hahn, Jin-Shei Lai (Northwestern University, Chicago, IL).
Funding
Work on this manuscript was supported by the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (R01NS077946), and the National Center for Advancing Translational Sciences (UL1TR000433). In addition, a portion of this study sample was collected in conjunction with the Predict-HD study. The Predict-HD was supported by the NIH, National Institute of Neurological Disorders and Stroke (R01NS040068), the NIH, Center for Inherited Disease Research (provided supported for sample phenotyping), and the CHDI Foundation (award to the University of Iowa).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Carlozzi, N.E. currently has research grants from the NIH; she is also supported by grant funding from the NIH, NIDILRR, and CHDI; she declares no conflicts of interest. Schilling, S.G. has a research grant from NSF. He also is supported by grant funding from NIH. He declares no conflicts of interest. Lai J.-S. currently has research grants from the NIH; she declares no conflicts of interest. Perlmutter, J.S. currently has funding from the NIH, HDSA, CHDI, and APDA. He has received honoraria from the University of Rochester, American Academy of Neurology, Movement Disorders Society, Toronto Western Hospital, St Lukes Hospital in St Louis, Emory U, Penn State, Alberta innovates, Indiana Neurological Society, Parkinson Disease Foundation, Columbia University, St. Louis University, Harvard University, and the University of Michigan. Nance, M.A. declares no conflicts of interest. Waljee, J.F. currently has research grants from the Agency for Healthcare Research and Quality, the American College of Surgeons, and the American Foundation for Surgery of the Hand; she declares no conflicts of interest. Miner, J.A. is supported by research grants from the NIH; she declares no conflict of interest. Barton, S.K. is supported by grant funding from the Huntington’s Disease Society of America, CHDI Foundation, and the NIH. She declares no conflicts of interest. Goodnight, S.M. is supported by grant funding from the NIH and the Craig H. Neilsen Foundation; she declares no conflicts of interest. Dayalu, P. currently has research grants from the NIH, Astra-Zeneca, and Vaccinex. He declares no conflicts of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Carlozzi, N.E., Schilling, S.G., Lai, JS. et al. HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Qual Life Res 25, 2417–2427 (2016). https://doi.org/10.1007/s11136-016-1273-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-016-1273-y